stenods of at had on major coronary vessel by quantitative coronary arteriaaraphy) was present to 131 pad" (ON vessel In 115; two vessels In 10, three vessels In 6), with normal coronary arterlography In 19. The Raslbility of the dipyridamoledohuhmine test was 96% . Selfaimalng side el6ets occaered In 5% of patients . The peak ate-peemare product was lowest during the dipyridamole test (132 t 30) and was comparable during the dobohmiee (186 A 59) and dipyrilamole-dohutamine teals (179 :b 45, p = NS vs. dubuhnlue; p < 0 .01 vs. dipyrldamle). Sedtivig was 71% for dlpyrWmok, 75% fer dobudamine mull 92% for dlpyridmala4ohofantim eeboeurdiography (dipyrtdamole vs. dlp)ridmohdobatamim, p < 0 .01; dabutamine vs , dipyridamolrdoiwWmhe, p < 0 .01; dipyrkhnele vs, dobnlambse, p = Nit), waerms specificity was 89% for dipyridamole, 79% for dobuhlie ad 89% for dipyridmndedobutanhe echocmdiograppy (p = NS for all).
Conclusion,. Routine dehummlne addition to dipyridesale stress tssteg is clkblly uwSel and well tolerated. It expands the spectrum of the disease detectable by pharmacobgle stress echocardiography and allows deamentedan of milder forms of carenary artery dham that ® be aniseed by usawad9nal dipyrldanole or dirhdm street Khmemulkwastisr . (J Am Call Cordial 1994; 23:1115-22) vessel coronary artery disease or evaluated during antianginal therapy (7) (8) (9) (10) (11) (12) . A theoretically attractive way of increasing pharmacologic stress cchocatdiographic sensitivity would be the com . bination in a single stress test of dipyridamole and dobutamine. They act through different and potentially synergic mechanisms because dipyridamole reduces subendocardial supply through flow maldistnbution phenomena, whereas dobutamine increases myocardial oxygen demand through increase in heart rate and contractility (13) . Furthermore, in the presence of a maximally dilated coronary bed, perfusion is critically dependent on the duration of diastole (14) , so that addition of a chronotropic stress to dipyridamole should also lead to a reduction in oxygen supply . However, to our knowledge a combined dipyridamoledobummim stress test has not been tried before . presumcily because of concern that combining these two potent cardiovascular drugs in doses four to six limes higher than therapeutic ones may result in serious side efecis . We therefore performed dipyridamole echocardiography in consecutive patients scheduled to undergo coronary aogiography ; In those patients with a negative test, it was repeated with dobutamine added . The feasibility, safety and diagnostic accuracy of the combined dipyridamdedabutamine echocardiographic lest were then assessed. Our working hypotheses were the 1) a combined dipyrldamoledobutnmloe echocardlographic stress teat would be sell: and feasible ; end 2) contllned dipyridamole and dobuicmine would have a synergistic action In provok . ins mymearaial iachemia .
Methods
Study gadNns. Patients with a history of ether typical or atypical effort pain, with or without previous myocardial infarction, were Initially considered . Patients with unsanble angina, cardiac failure, severe congenital or valvular been disease, conduction disturbances or documented cardi0my-apathy were excluded from tine study . Patients with sevens hypertension (systolic pressure X200 mm Hg, diastolic pressure >120 mm Hg) and recent muligimas ventricular arhythmiss were also excluded because these omdittions represent a contraindication to dobutamine stress . Patients with severe asthmatic disease requiring long-term therapy with oral phyllines were excluded as well because dipyridamole suns is ineffective in this situation (phyllirie blocks the adenosine receptors). All patients with previous myocardial Infarction wore studied at least 4 weeks after the sent-event . An initial group of 150 patients (mean [±SD] age 51 ± I I years) were evaluated and underwent dipyridamok echocardiogiaphic JACC Vul. 23, No. 5 April 1994:1115-22 tenting. Of these, 95 partners had a positive test and were excluded from further combined testing, The ramainiog 55 patients (45 men, t0 women, mean age 50 2:12 years, rang 28 to 71) had a negative dipyridaumk echaeardiopaphic tat and underwent combined dipyeidamole •d obntamine echocardiagtaphie testing on the following day. The same Initial set of 150 patients alw had a dobuumine echocardlographic test oi. a separate day but within 3 days of the dipyridamole and dipyridamole-dobutamine eehocardiographic tests . Moat patients had eoGang(vl therapy as the then of went testing (Table 1) . Dlsttlbmion of dinial forms of coronary artery disease in the 150 patients was Q wave myocardial inftaalon h 38 (25%), nms .Q wave myocerdhd h$relion in 38 (25%), mdna in 79 (39%) and Mypksl chest paid in 15 (10%) . D(pytliamdle was to, Dipytidam old was Infused at a rate of 036 mg/kg body weight for 4 min, followed by 4 min of m dose add then 0.23 esg/kg in 2 min. The cumulative dose was therefore 0.84 mg/kg for 10 min. Dobutarie stress to . Dobutemine was infused by means of a mechanical pump, atoning at a dose of 5 4kg per min for 3 min. progressing to 10 pplkg per min for 3 dirt and then increasing ht 3-mis Intervals w 20,30 and 40 jug/kg per min, except for the lass 9°m of 40 pglkg per mid, which hod for 5 min .
Diysldsaele'dahalmWe arm tat, Dipyridamole was given with the usual Infusion protocol (up to 0 .84 mg/hg in 10 min). At the end of the infusion, dobutamine infusion was started with tine usual protocol up to 40 pkkg per min (Pig. 1). Amieighylline ad proprenolol were available . Aminophylline (40 to 70 mg fort min) was always given, in negative tests as well, at the fifth mitre from the end of dobutamise administration.
Ted mdbodaklgy . After routine preparation for stress testing and insertion of an hbtmvenous line, rest electrocar diopaphy ad two-dimensional echocardiography were per- new at_" dabnormal wall motion were identified in multiple views whenever possible . The videotapes were analyzed by the cardiologist-echocatdiographer perfuming the study . who was unaware of the clinical and engiographic data A digital acquisition of images of interest was performed, and a side by side display of rest and peak stress images in a doe-loop mode was obtained, Positivity of the test was based on the detection of transient dyssyoetpy of wnlrac Lion, which was absent or of a lesser degree in the baseline examination . Only eehoeardiographle criteria (a new or worsening wall motion abnormality) were considered as positive tests. Neither the presence of a rest welt motion abnormality nor the presence of stress-induced angina or ischemie ECO changes were considered positive test results . A high level l>90Y) of interobsetver and intraobaerver reproducibility of stress echocardiography readings in our labtnatory among experienced observers has previously been shown (15) . A wall met= score i dew was derived for rest and peak stress echocardiograms in each patient by consensus between the two observers . The left ventricle was divided Into 11 segments : apex: proximal and dislel septum: proximal and distal inferior septum ; proximal and distal anterior wall ; proximal and distal lateral wall ; proximal and distal inferior wall, Segmental wall motion was graded as 'ollows: I (normal) = normal motion at rest, with normall increased wall motion (hyperkinesial after stress ; 2 (hypokioetic) = marked reduction of endocardial motion : 3 (aki.setic) = virtual absence of inward motion ; 4 (dyskinetic) = pamdoxic wall motion away from the left ventricular center OSTOJSC ET AL . 1117 DIPYRIOAMOLE.UOEV-rAMINE STRESS ECHOCARDIOGRAPHY in systole . The wail motion score index was derived by summation of individual segment scares divided by the number of interpreted segments . Inadequately visualized segments were not seemed, Fnd paints of the test were the achicvcmcnt of peak dose, development of obvious echuesrdiographic positivity . severe angina. diagnostic (>0.2-mV ST segment depression) ECG positivity or the occurrence of severe, limiting side effects . These included hypertension (systolic pressure >770 mm Hg, diastolic pressure >120 mm Hg) . hypotension (>20-mg Hg decrease in systolic pressure) . bradycaedia, dyspnea or complex arrhythmias (atrial fibrillation or supraventricular tachycardia ; frequent, polymolphuus or repetitive ventricular premature beats alone or in combination) .
Angiographie study. Patients underwent single-plant left ventriculography and selective right and left coronary arse . riography using either the ludkins or Suites technique. Multiple views of each coronary artery were obtained, including cruniocaudal views. After visual inspection of the coronary arteries in all views, the ftwue in which the most severe lemon appeared was selected and analyzed . after off-lire digiriratum, by an array processor-based computer for medical image processing (Mipron . Kontroa or MEDIS). Coronary artery disease was considered present if the diameter of at least one major coronary artery was narrowed ?50h with respect to presteuocic tract . An experienced observer, unaware of the results of the noninvasive tests . analyzed the coronary aagiograms.
Statistical analysts . Data are expressed as mean value '_ SD . Comparisons between groups for continuous data were made with the Student t test. Sensitivity and specificity in detecting angiopaphically assessed coronary artery disease were calculated according to standard definitions . Differences between the results of the dipyridamole, dobutantine and dipyridamole-0obutamine echocardiographic tests were compared by means of the chi-square test; a Fisher exact test was used when appropriate . Differences between groups with regard to minimal lumen diameter and percent of diameter steuosis were analyzed by analysis of variance . A probability value of p < 0.05 was accepted as statistically significant .
Iffegults
A total of 150 patients were considered for analysis . All patients had a dipyridamole echocardiographic test and, 'in a separate dny, a dobutamine echocardiagraphic test . Those patients with a negative dipyridamole echocardiugraphic test progressed I, combined dipyridamole-dobutantine echocardiographic testing .
Anglographle findings. (Table 2) . Overall sensitivity and specificity for coronary artery disease were 71% (95% confidence interval ICI] 63% to 79%) and 89% (95% Cl 76% to I00%) ( Fig. 2  and 3 ). Dobutemlne uroerdisgrephle had fhsBogo. The dobutamine echocardiographic test could be completed m 98% of patients. In 2% of patients, limiting side effects precluded the achievement of a predetermined end point (Table 2) . Overall sensitivity and specificity for memory artery disease were 75% (95% Cl 67% to 82%) and 79% (95% CI 61% to 97%, p NS vs. dipyridamae echoardiographic test) (Fag. 2 and 3).
Nine patients with coronary artery disease and a positive dipyridamole study had a negative dobutamine study, whereas 14 patients with coronary artery disease and a negative dipyridamale study had a positive dobutamine study Conversely. of the Four patients with no coronary artery disease who had a "false positive" dobmamine study, one also had a positive dipyridamole study. Of the two Pew 2. Bar graph showing sensitivity of dipyddamok (DE) . dobutamine (DOBET) and dipyridamok-dohutamise (DIPDOB) echocardiography. The latter provide a clear step up k sensitivity versus the other two tons . Sensitivity ordlpyridamula'dohetandoe echucardiaeraphy was calculated as cumulative, considering It as a single test with two stages. sensitivity (%) ' pe0.01 patients with no coronary artery disease who had a "false positive" dipyridanmle study . one also had a positive dobulamine study.
The overall concordance between dipyridamole and dobatamine stress ecbocardiogtaphie results concerning positivtty or negativity was 8E%. Good agreement was observed with regard to the extent and severity of stress-induced dyssynergy . In fact, there was a significant correlation between the peak dipyridamole and peak dobulandines wall motion score indexes (r -0.71, p < 0.01).
Fate y and soft. Interpretable images were obtained in all dipyridamole-dobutamine studies . In two patients the peak dipyridamde-dobmandes: dose was not completed despite echocardiography negativity for limiting aide effects (vomiting in one patient at 20 pa/kg per min, symptomatic hyposamion in one patient at 20 pp/kg per min) . Of these two patients notes had significant coronary artery disease . In one patient severe hypertension occurred at 5 ,vg/kg per min, and that patient had a true positive result . In 35 patients (64%) . some side efipets occurred during dipyridamoledobummine stress (chilling tremor in 31%, prepmtule ventricular contractions in 13%, headache in 20%, nausea in 9%, flush oo in 7%, dyspnea in 2% patients (36%), dipyridamole-dobummine tests were accomplished without any side effects. The overall feasibility (that is, P-hieveotem of peak dose or target heart raw or echocarapbic positivity) of the dipyridamole-dobsmmine test was 96% (p = NS vs . dipyridamole lest . 10000, and vs. dnbutmnine rest, 98%). In 27 patients with eehueardiugaphy positivity for ischentia and in 10 patients with side effects, signs of ischemia or side effects, or both . were promptly reversed by stopping the dobummine infusion and aminophyllinc injection. No patients received intravenous proprano)ol.
Hemodyoamlc mss. Changes in heart rate, blood pressure and rate-pressure product with dipyridamole alone . dobutamine aim and combined dipyridattmle-dobummiae are shown in Table 2 . Peak heart rote during the dipyridamoledobutemine test was similar to that observed with dobummine alone and significantly higher than with dipyridamele alone, Peak systolic and diastolic blood pressures were significantly lower during dipyridaowle-dobutamine tests than during debutamine alone (p < 0 .01 and p < 0.05. respectively). Heart rate-pressure product Itaponse was lower during combined dipyridamole-dobutnmine tests than during dobutamine alone but did not reach statistical significance. That pattern was consistently observed even when eehocardiogaphicahly or angiogaphically, or both, positive eases versus negative cases were analysed .
Diepmde stoma y d dilitysl adolmaaine echoor• d ap . . lesthng far roraoary artery disease . The overall sensitivity of the dipyridamdedobutamine echocardiographic teal for coronary artery disease was 92% (95% C1 87% to 98%. (p < 0.01 vs. dipyridamole and vs . dobutamine) IFIg, 2) . The overall specificity of the dipyridamoledobotamine echocardiographic test for coronary artery disease was 19% (95% CI 76% to 100%) (P -NS vs . dipyridamde and vs. dabutamine) (Fig . 3) . The addition of dobutamim to dipyridamole raised the sensitivity of the test from 71% to 91%. with no loss in specificity, by identifying an additional 27 patients with coronary artery disease . Although the sensitivity of the combined lost was 9246, the sensitivity ofdipyridamole-dobmamine echocardiography in the Mats of 55 patients was actually 71% (27 positive tests in 38 patients with coronary artery disease), whereas the specificity wait LOD% 417 of 17 true negative ratings). In 14 of 27 patier:s with echocardiogmphic positivity. the dipyridamole-Ifobutamine tat wait accompanied by chest pain, and in 14 patients significant ST segment depression also occurred . Of the 28 negative dipyridamole-debutamine tests by echtscsrdiographic criteria, chat pain was present in eight patients, and significant ST segment changes were noted in one patient. In 7 patients with and 31 patients without real wall motion abnormalities, we found no difference (p = NS) with regard to the sensitivity of dipyridamole dobatamine echocardiography to detect myocardial ischemia: 5 (71%) of 7 patients with rest wall motion abnormalities had a positive dipyridamole-dobulamiec echoeasdioge.phic test, and 22 (71%) of 31 patients wish normal rest wall motion had a positive dipyridamoledobutemine echocardiegraphic test . In 27 patients with a positive dipyridamole-dobummine test, the wall motion score index went from 1 .04 ± 0.12 at baseline to 1 .31 ± 0.11 at peak dipyrdanole-dobutamine testing (p < 0.01). A positive result to the dipyridamole-dobutmmine test occurred in 2 patients -.Met the first dobmamine dose (5 A8/k8 per min). in'-patients after the second dose (10 Yglkg per mitt). in 9 patients after the third dose (20 *kg per min), in 2 patients after the fourth dose (30 pg/kg per min) and in 12 patients after the last dose (40 µglkg per min) .
Test results related to coronary arteringraphic Oadiega . There was a clear-ad tendency of a positive low dose dipyridamole stress test to detect patients with the most severe coronary artery disease, whereas negative dipyridamule-dobutarnine cehocardiography identified most accurately patients without significant coronary artery disease (p < D.05) (Table 3) .
When only the patients whh single-vessel disease were considered, the values of percent diameter slenosis tended to be worse in the 79 patients with a positive dipyridamole echocardiographic test (68.1 a: 9 .fi%) compared with the 25 patients with a positive dipyridamoledobmamine echocardiographic test (6(9 ± 13 .1%). The values were lowest in patients with a negative dipyridamolc-dobutamine echocardiographic test (62 .3 ± 7.4%, p = NS for all intergroup differences) . A similar trend was found for minimal lumen diameter, which was 0.98 ± 0 .3 mm in patients with a positive dipyridamole echocardiographic test, 0 .88'_ 0 .4 mm in patients with a positive dipyridamok-dobutamine echocardiogmphic test and 1 .11 ± 0.24 men in pn ' :nts with a negative dipyridamale-dobummine echocardiographic test (p = 0 .074 for all intergroup differences) .
Discussion
According to this initial experienc-, the dipyridamole dobutamine echocatdiographic test is feasible and safe. with high diagnostic accuracy for the detection of angiographi- tally assessed coronary artery disease even in patients with relatively minor forms of coronary artery disease, as shown by the negative results of the dipyridamole echocardiographic test.
Patkogenetk meckanlsme of lachemfe daring dip)Tidamde • dobuts mine tesing . Tests exploring organic coronary stenosis can induce isehemia through two basic mechanisms : I) an increase in oxygen demand, exceeding the fixed supply ; and 2) How maldistrihution due to inappropriate coronary arteriolar vesodilation triggered by a metabolic or pharmscologic, or both, stimulus (13). These two pathways can be safely and effectively combined in a single test, as shown by the accuracy or the dipyridamole exercise stress test to detect milder forms of coronary artery disease (16). After dipyridamole administration, a alight increase in myocardial function, a modest decrease in blood pressure and mild taehycardia can be observed, globally determining only a trivial increase in myocardial oxygen demand . Dipyridamole provokes ischemia mainly through flow maldistrlbution phenomena, ultimately determining a decrease in absolute sob endocardial flow (17). The biochemical effector of this hemodynamic mechanism is the inappropriate accumulation of adenosine, which is the main physiologic modulator of coronary arteriolar vasodilation because dipyridamole inhibits the cellular reuptake of endogenously produced adenoaine (1) . Dobutamine superimposes a marked inolropic and chronotropic stress on dipyrid_ .nole (whose effects last >20 min after stopping the infusion), substantially increasing myocardial oxygen demand . Furthermore, in a maximally vasodilated bed, myocardial perfusion Is almost entirely diastolic (18); accordingly, the frequency Increase reduces the perfusion time and may lead to a further reduction in myocardial oxygen supply, especially in the aubendocardial layer (19--21) .
Comparison with previous studies . Dipyridamole and dabutnmlae stress accuracy. As a by-product of its design our study also allowed a direct comparison between dipyridamole and dahutnmine echocardiographic tests, Several reports have been published in this regard in bath the experimental (22.23) and clinical (7.9-11) setting. In animal experiments, a higher frequency of transient dyssynergy with dobutamine than with dipyridamole (100% vs . 56%) was reported. However, submaximal doses of both dipyridamole (0.56 mg/kg) and dobutamine (I5 pglkg per min for IS min) were used In that study (22) . When appropriately high doses of dobutamine (40 pg/kg per min) and dipyridamole (0.7 mg/kg) were used, a similar effect on regional left ventricular function was detected (23). In the clinical setting, there are three published reports on the direct comparison of the two tests, all describing similar diagnostic accuracy (7 .9,10) . When these studies are considered together . there is a trend toward a marginally superior sensitivity for dobutembne (67% vs . 59%, p = NS) and a marginally superior specificity for dipyridamole (82% vs . 71%, p = NS). Our results, in by far the largest patient group studied to date, are in agreement with these experimental and clinical data because in the group that underwent both tests separately, diagnostic accuracy was similar (24), although dipyridamole tended to have a slightly higher specificity and slightly lower sensitivity . The moderate sensitivity of the two tests should be considered in light of our study patients, most of whom had single-vessel disease and in whom the sensitivity of these tests was lower compared with pa ients with multives. sel disease (2,9), who were studied while receiving antiamgisal therapy (which further lowers the sensitivity of both dipyridamole and dobutamine echocardiography) (8, 12) . Furthermore, our results are also consistent with those of Marwick et al . (25) who found that high dose adenosine had a similar specificity to dobutamine echocardiography, with a lower sensitivity in single-vessel coronary artery disease . However, up to 25% of patients could not tolerate maximal adenosine doses, and this may well explain the sensitivity gap because dipyridamole is much better tolerated than adenosine.
Safety and effectiveness ofeamblined testing. It has been shown in > 10,660 dipyridamole cchocmdiopsphic tests that nearly all serious side effects occur within 10 min of the test (26) . This led us to presume that immediate dobutamine infusion after a negative full-dose dipyridamole test would be safe. In our study, we did not observe either major side effects or prolonged, antidote-resistant ischemia after dipyridamole .dobutamine costing. This may be due to the fact that all patients receiving ddwtamine had already had a negative result with dipyeidamole alone, and most of them also had a negative result with dottutamine alone, and therefore more severe, extensive or hemodynamically ins. pmtant degrees of coronary disease had been ruled out .
Several modified protocols of dipyridamole eclmcardiographic costs have been proposed to increase the pharmaco logic stress eehoeardiography sensitivity, including handgrip (27.28). dynamic exercise (16). tmnseaophageal pacing (29) and atropine (30) in addition to dipyridasnole infusion . The dipyridensck-dobmamine tchocardiographic lost has some advantages over other combined approaches that have been proposed to Increase dipyridamole echocardiographie test sensitivity: It is not dependent on physical effort, as in the combined dipyridanwlcexerclse test; it is mom sensitive than the dipyridamole-handgrip test ; and h is totally noniovasive, unlike the dipyridamole-transesophogeal pacing test . However, compared with the dipyridamoleetropine test, it more frequently induced limiting side effects, mad the echocardiography image quality was somewhat lowered by the greater inotropic and tachycardlac effect of dobtttamine . Furthermore, imaging time is substantially longer with the dipyridansole-dahutamine test than with the dipyridamole atropine test . These relative disadvantages should be weighed against the capability of the dipyridamoledohutamine test to generate even stronger ischemic stress to the myocardium, as reflected by the excellent sensitivity achieved in patients with negative results on conventional stress tests and minor forms of coronary artery disease, as Apta i554:t115-22 DIPYRIDAMOLE-DDaUTANlNE SJRnSS CCHOCARPIaORAPHY well as by the greater increase in heart rate and blood pressure observed alter the dipyridamcle-dobutamine lest compared with the dipyridamole-atropine test .
Study imWUoas. Our patients were studied en a consecutive basis, but it should be pointed out that Belgrade University Institute for Cardiovascular Disease is a tertiary care referral center for coronary angioplasty . This may well explain the unusually high percent of patients with singlevessel disease .
Almost 90% of the patients were receiving antianginal therapy a the time of testing, and 47% received betaadrenergic blocking agents. It is well known that the sensitivily of both dobutamine (31) and dipyridamole 1121 echucardiography decreases significantly when the tests ate performed during medical therapy. One may therefore hypothesize that after interruption of treatment (usually feasible bug often impractical in patients in stable condition referred for diagnostic evaluation, as were those described in this study). the sensitivity of both dipyridamule and dobutamine alone would have been similar to that of the combined test during medical therapy. Thus, the adjunctive diagnostic value and the clinical role of ibis new test would love been better assessed in a group of patients not receiving medical therapy . The presence of medical therapy also certainly contributed to obscure line correlation between coronary sleaosis severity and stress test results in patients with single-vessel disease.
Another limitation is that we used conventional high dose regimens far dipyridamole (up to 0.81 mglkg) and dobutamina (up 1040 rtglltg per min). For both tests, this infusion protocol cannot be considered truly state of the an because it was recently shown that atropine (up to I mg for 4 min) addition further increases test sensitivity without decreasing specificity for both dohulantine (g) and dipyridamole (301 echocardogaghy.
Finally. although the test proved safe and feasible, its completion in the case of a negative study takes at least 27 min . whleh is relatively time-consuming for both the physician and technician Involved in performing the study and has the potential to adversely affect patient tolerance .
C11ieal hupHeatlmu. Efficacy, tolerability and ease of execution make dobwamme a suitable pharmacologic coon panion of dipyridamole stress testing when dyssynetgy, and therefore isthemia . Is the diagnostic end point . It is equally obvious, however, that large-scale experience at this point is needed because initial feasibility studies an a new lest slheuld not be inappropriately viewed as a validation, and, according to Diamond (32), them is a big difference between the seed of efficacy and the fruit of effectiveness. It is attractive to propose dobutamine addition, in a scalar stepwise fashion, in all patients with a high dose dipyridamole test that continues to be negative, so as to increase the sensitivity of !he test with no loss in specifidty and only a moderate prolongation of imaging time . Although the diagnostic domain of the dipyridamole dobummin echocadographic test remains =clear, its advantages might make it a very attractive choice in patients with clinically suspected ischemic heart disease and negative results on conventional stress test procedures. 
